-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Fibromun in Malignant Glioma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Fibromun in Malignant Glioma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Fibromun in Malignant Glioma Drug Details: Fibromun (L19-TNF alpha monoclonal antibody-cytokine...
-
Product Insights
NewQuarterly Hot Coffee pricing trends in Japan
Empower your strategies with our Quarterly Hot Coffee pricing trends in Japan report and make more profitable business decisions. Consumers’ preferences for stores are most heavily influenced by pricing and promotions, but brands and retailers continue to adjust prices and promotions based on insufficient information from expensive, drawn-out, and incomplete audits of rival techniques. Brands and retailers can benefit from the unique intelligence provided by GlobalData Ecommerce Price Tracker, covering millions of SKUs, to identify, anticipate, and implement important business...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Edoxaban Tosylate in Chronic Thromboembolic Pulmonary Hypertension
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Edoxaban Tosylate in Chronic Thromboembolic Pulmonary Hypertension report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Edoxaban Tosylate in Chronic Thromboembolic Pulmonary Hypertension Drug...
-
Product Insights
NewQuarterly Hot Coffee pricing trends in the United States
Empower your strategies with our Quarterly Hot Coffee pricing trends in the United States report and make more profitable business decisions. Consumers’ preferences for stores are most heavily influenced by pricing and promotions, but brands and retailers continue to adjust prices and promotions based on insufficient information from expensive, drawn-out, and incomplete audits of rival techniques. Brands and retailers can benefit from the unique intelligence provided by GlobalData Ecommerce Price Tracker, covering millions of SKUs, to identify, anticipate, and implement...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Acalabrutinib Maleate in Lymphoproliferative Disorders
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Acalabrutinib Maleate in Lymphoproliferative Disorders report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Acalabrutinib Maleate in Lymphoproliferative Disorders Drug Details: Acalabrutinib maleate (Calquence)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – JAB-2485 in Solid Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. JAB-2485 in Solid Tumor Drug Details: JAB-2485 is under development for the treatment of RB1...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Glecirasib in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Glecirasib in Solid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Glecirasib in Solid Tumor Drug Details: Glecirasib (JAB-21000) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Glecirasib in Pancreatic Ductal Adenocarcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Glecirasib in Pancreatic Ductal Adenocarcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Glecirasib in Pancreatic Ductal Adenocarcinoma Drug Details: Glecirasib (JAB-21000) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Glecirasib in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Glecirasib in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Glecirasib in Non-Small Cell Lung Cancer Drug Details: Glecirasib (JAB-21000)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – JAB-2485 in Small-Cell Lung Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. JAB-2485 in Small-Cell Lung Cancer Drug Details: JAB-2485 is under development for the treatment of...